These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 12506189

  • 1. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K, Potti A, Mehdi SA.
    J Clin Oncol; 2003 Jan 01; 21(1):172-3. PubMed ID: 12506189
    [No Abstract] [Full Text] [Related]

  • 2. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.
    Larson JS, Bergstrom LK, Cameron JD, Erickson LA, Grimm TE.
    Arch Ophthalmol; 2007 Jul 01; 125(7):985-6. PubMed ID: 17620589
    [No Abstract] [Full Text] [Related]

  • 3. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G.
    Leuk Res; 2008 Jul 01; 32(7):1022-5. PubMed ID: 18061664
    [Abstract] [Full Text] [Related]

  • 4. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D, Lipton J.
    Leuk Lymphoma; 2007 Jan 01; 48(1):195-6. PubMed ID: 17325868
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hypersensitivity pneumonitis related to imatinib mesylate.
    Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, Socié G, Calvo F, Gluckman E, Ribaud P, Rousselot P, Tazi A.
    J Clin Oncol; 2002 Oct 15; 20(20):4271-2. PubMed ID: 12377975
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M, Gossart M.
    Pol Arch Med Wewn; 2013 Oct 15; 123(5):251-2. PubMed ID: 23722191
    [No Abstract] [Full Text] [Related]

  • 11. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y, Aksu S, Kekilli M, Haznedaroglu IC, Kilickap S, Goker H.
    Am J Hematol; 2005 May 15; 79(1):79-80. PubMed ID: 15849758
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.
    Georgalas I, Pavesio C, Ezra E.
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct 15; 245(10):1585-6. PubMed ID: 17562067
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interstitial pneumonitis during imatinib therapy.
    Isshiki I, Yamaguchi K, Okamoto S.
    Br J Haematol; 2004 May 15; 125(4):420. PubMed ID: 15142112
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK, King RS.
    Cancer Pract; 2001 May 15; 9(5):263-5. PubMed ID: 11879324
    [No Abstract] [Full Text] [Related]

  • 20. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX.
    Leukemia; 2003 May 15; 17(5):978-9. PubMed ID: 12750713
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.